Inactive Instrument

Quotient Limited OTC Markets

QTNT

JE00BNNSZY03

Quotient Limited to Participate in the Cowen 38th Annual Global Health Care Conference

March 01, 2018 at 04:06 pm EST

JERSEY, Channel Islands, March 01, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive Officer, Paul Cowan, will present at the Cowen 38^th Annual Global Health Care Conference on Tuesday, March 13^th, 2018 at 8:00 a.m. EDT at The Boston Marriott Copley Place, in Boston, MA. The Company's Chief Financial Officer, Chris Lindop, will also be participating in the conference.

A webcast of the presentation will be available online from the investor relations page of the Company's corporate website at www.quotientbd.com. A webcast replay will be archived on the website for approximately 90 days.

About Quotient Limited

Quotient is a commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the provision of innovative tests within established markets. With an initial focus on blood grouping and serological disease screening, Quotient is developing its proprietary MosaiQ™ technology platform to offer a breadth of tests that is unmatched by existing commercially available transfusion diagnostic instrument platforms. The company's operations are based in Edinburgh, Scotland; Eysins, Switzerland and Newtown, Pennsylvania.

The Quotient logo and MosaiQ™ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.

CONTACT: Chris Lindop, Chief Financial Officer — chris.lindop@Quotientbd.com; +41 (0)799 61 69 38

Latest news about Quotient Limited

Quotient Limited Appoints James Harman Gaudin to its Board of Directors	23-06-14	CI
Certain Ordinary Shares of Quotient Limited are subject to a Lock-Up Agreement Ending on 23-SEP-2022.	22-09-22	CI
Certain Restricted Share Units of Quotient Limited are subject to a Lock-Up Agreement Ending on 23-SEP-2022.	22-09-22	CI
Certain Options of Quotient Limited are subject to a Lock-Up Agreement Ending on 23-SEP-2022.	22-09-22	CI
Certain Warrants of Quotient Limited are subject to a Lock-Up Agreement Ending on 23-SEP-2022.	22-09-22	CI
Transcript : Quotient Limited, Q4 2022 Earnings Call, Jun 24, 2022	22-06-24
Quotient Limited Provides Earnings Guidance for the Fiscal Year 2023	22-06-24	CI

Chart Quotient Limited

Duration

Period

More charts

Company Profile

Quotient Limited is a Switzerland-based diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market. It is engaged in developing MosaiQ, which is its technology platform. The Company develops, manufactures and commercializes the products, including antisera products, reagent red blood cells, whole blood controls and ancillary products. Additionally The Company develops, manufactures and sells conventional reagent products to original equipment manufacturers (OEMs).

Sector

Pharmaceuticals

More about the company